Lupin shares rise on US launch of kidney drug Tolvaptan; $200 million revenue seen by FY26

Lupin shares rise on US launch of kidney drug Tolvaptan; $200 million revenue seen by FY26

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Lupin Ltd. edged 2.5 percent higher on Wednesday after the company announced the launch of Tolvaptan tablets in the US market, marking a key milestone in its US generics portfolio. The drug is a therapeutic equivalent of Jynarque, developed by Otsuka, and is used to treat autosomal dominant polycystic kidney disease (ADPKD) — a chronic condition with limited treatment options.

CNBC-TV19 reported the significance of this launch as a meaningful addition to Lupin’s US pipeline, with analysts estimating that the product could generate $200 million in annual revenues by FY26, assuming steady uptake and pricing stability. Jynarque is a relatively niche drug in the nephrology space but commands a strong pricing premium in the US market due to limited competition. Analysts believe the US generics opportunity remains a critical pillar in Lupin's recovery strategy, especially as the company focuses on complex products and specialty therapies to rebuild profitability.

The launch also comes at a time when the Indian pharmaceutical industry is seeing a revival in US-bound product approvals and pricing stability after years of regulatory pressure and intense price erosion. This latest development follows a string of approvals Lupin has received from the USFDA in recent quarters, reinforcing its positioning in the complex generics segment. At last check, Lupin shares were trading higher on the NSE, extending recent gains fueled by a combination of steady earnings and strategic product launches in regulated markets.

READ MORE: Pharma Q4 preview: Lupin, Sun Pharma, Cipla among top sectoral picks across brokerages

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.